Redwood City, CA – According to filings with the U.S. Securities and Exchange Commission, Bolt Biotherapeutics is raising $40,103,799.00 in a new round of investment. Sources indicate as part of senior management Chief Business Officer, Grant Yonehiro played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Bolt Biotherapeutics

Bolt Biotherapeutics is a vibrant biotechnology company actively developing its novel Boltbody platform, a cancer immunotherapy that consists of Immune-Simulating Antibody Conjugates (ISAC). Located in the San Francisco Bay Area, Bolt is led by a team with extensive oncology drug development experience and is seeking bright, self-motivated individuals who share their passion for bringing novel and curative biotherapies to patients in need.

To learn more about Bolt Biotherapeutics, visit http://boltbio.com/

Contact:
Grant Yonehiro, Chief Business Officer
650-665-9295
gyonehiro@boltbio.com
https://www.linkedin.com/in/grantyonehiro/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved